EOHILIA™ (budesonide oral suspension) is an FDA approved 12-week oral treatment for EoE in people 11 years and older. It has not been shown to be safe and effective for longer than 12 weeks. Website …

Patient access info for EOHILIA™ (budesonide oral suspension) treatment. Website for U.S. Healthcare Professionals. See Important Safety Information and Full Prescribing Information.

Mar 17, 2025 · Historic EoE Treatments Eohilia is the first FDA-approved medication specifically designed for the treatment of EoE. It is an oral suspension of budesonide, a corticosteroid that …

UnitedHealthcare Pharmacy Clinical Pharmacy Programs ... Background: Eohilia (budesonide oral suspension)* is a corticosteroid indicated for 12 weeks of treatment in adult and pediatric patients 11 …

Oct 15, 2024 · Eohilia (budesonide) is a corticosteroid that's FDA approved to treat eosinophilic esophagitis (EoE) in adults and children. The dosage is typically a packet taken by mouth twice daily …

Learn how EOHILIA™ (budesonide oral suspension) works for eosinophilic esophagitis (EoE) treatment and how to take it. See Important Safety Information and Prescribing Information.

Feb 12, 2024 · FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)

Learn why EOHILIA™ (budesonide oral suspension) may help treat your eosinophilic esophagitis (EoE) patients 11 years and older. See Important Safety Information and Full Prescribing Information.

Feb 14, 2024 · The FDA approved the first oral suspension of budesonide (Eohilia, Takeda) for patients with eosinophilic esophagitis who are 11 years of age and older.

Patient resources for EOHILIA™ (budesonide oral suspension) including a starter kit, downloadable guides, FAQs, and a glossary. For U.S. residents only. See Important Safety Information and …